Literature DB >> 8551636

Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus.

N D Christensen1, C A Reed, N M Cladel, R Han, J W Kreider.   

Abstract

Rabbits were immunized with recombinant baculovirus-produced virus-like particles (VLPs) of cottontail rabbit papillomavirus (CRPV) to determine whether these antigens could induce long-term protection against experimental challenge with CRPV. Infectious CRPV and human papillomavirus type 11 L1 VLPs were used as positive and negative control immunogens, respectively. Three groups of immunized animals were challenged with 10-fold serial dilutions of infectious CRPV at 2 weeks, 6 months, and 12 months after immunizations. Antibody titers in serum reached 1:10,000 immediately after the final booster immunization and then decayed to 1:150 at 6 months and 1:100 at 12 months in unchallenged rabbits. Serum neutralization titers followed similar kinetics. Papillomas grew on control-immunized rabbits at sites challenged with 10(-1) (100% of sites), 10(-2) (96% of sites), 10(-3) (63% of sites), and 10(-4) (13% of sites) dilutions of virus. At 2 weeks after CRPV L1 VLP immunizations, the rabbits were completely protected against virus challenge. At both 6 and 12 months after CRPV L1 VLP immunizations, strong protection was also observed. In the last two groups, three of seven rabbits were completely protected and only 4 of 14 or 29% of sites challenged with 10(-1 dilution of virus grew papillomas. Papillomas growing at these four sites were also reduced in size (3.5 +/- 0.7 mm) at 50 days postchallenge compared with sites challenged with 10(-1) dilution on control-immunized rabbits (13.2 +/- 4.2 mm). The results demonstrate that strong and long-lasting protection against experimental challenge with papillomaviruses can be achieved with VLP immunogens.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8551636      PMCID: PMC189900     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

Review 1.  CUTANEOUS PAPILLOMATOSIS IN CATTLE AND OTHER ANIMALS.

Authors:  C OLSON
Journal:  Ann N Y Acad Sci       Date:  1963-11-04       Impact factor: 5.691

2.  Comparison of neutralization of BPV-1 infection of C127 cells and bovine fetal skin xenografts.

Authors:  S Ghim; N D Christensen; J W Kreider; A B Jenson
Journal:  Int J Cancer       Date:  1991-09-09       Impact factor: 7.396

3.  Studies on vaccination against papillomaviruses: the immunity after infection and vaccination with bovine papillomaviruses of different types.

Authors:  W F Jarrett; B W O'Neil; J M Gaukroger; K T Smith; H M Laird; M S Campo
Journal:  Vet Rec       Date:  1990-05-12       Impact factor: 2.695

4.  The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes.

Authors:  N D Christensen; J W Kreider; N C Kan; S L DiAngelo
Journal:  Virology       Date:  1991-04       Impact factor: 3.616

5.  Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.

Authors:  R Kirnbauer; F Booy; N Cheng; D R Lowy; J T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

6.  Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles.

Authors:  J Zhou; X Y Sun; D J Stenzel; I H Frazer
Journal:  Virology       Date:  1991-11       Impact factor: 3.616

7.  Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins.

Authors:  M E Hagensee; N Yaegashi; D A Galloway
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

8.  Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles.

Authors:  R C Rose; W Bonnez; R C Reichman; R L Garcea
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

9.  Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus.

Authors:  Y L Lin; L A Borenstein; R Selvakumar; R Ahmed; F O Wettstein
Journal:  Virology       Date:  1992-04       Impact factor: 3.616

10.  Expression of the major capsid protein of human papillomavirus type 16 in Escherichia coli.

Authors:  S R Kelsall; J K Kulski
Journal:  J Virol Methods       Date:  1995-05       Impact factor: 2.014

View more
  50 in total

1.  Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection.

Authors:  Subhashini Jagu; Kihyuck Kwak; Robert L Garcea; Richard B S Roden
Journal:  Vaccine       Date:  2010-04-29       Impact factor: 3.641

Review 2.  HPV-vaccination against cervical carcinoma: will it really work?

Authors:  Gerd Gross
Journal:  Med Microbiol Immunol       Date:  2007-02-21       Impact factor: 3.402

3.  Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles.

Authors:  Timothy D Culp; Christin M Spatz; Cynthia A Reed; Neil D Christensen
Journal:  Virology       Date:  2007-01-12       Impact factor: 3.616

4.  Secondary infections, expanded tissue tropism, and evidence for malignant potential in immunocompromised mice infected with Mus musculus papillomavirus 1 DNA and virus.

Authors:  Nancy M Cladel; Lynn R Budgeon; Timothy K Cooper; Karla K Balogh; Jiafen Hu; Neil D Christensen
Journal:  J Virol       Date:  2013-06-19       Impact factor: 5.103

5.  Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications.

Authors:  Maxime J J Fleury; Antoine Touzé; Marie-Christine Maurel; Thierry Moreau; Pierre Coursaget
Journal:  Protein Sci       Date:  2009-07       Impact factor: 6.725

Review 6.  On the relevance of defining protein structures in cancer research.

Authors:  Inés G Muñoz; Franciso J Blanco; Guillermo Montoya
Journal:  Clin Transl Oncol       Date:  2008-04       Impact factor: 3.405

Review 7.  The role of vaccines in the control of STDs: HPV vaccines.

Authors:  I H Frazer
Journal:  Genitourin Med       Date:  1996-12

8.  Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease.

Authors:  Jon D Reuter; Beatriz E Vivas-Gonzalez; Daniel Gomez; Jean H Wilson; Janet L Brandsma; Heather L Greenstone; John K Rose; Anjeanette Roberts
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

Review 9.  Papillomavirus prophylactic vaccines: established successes, new approaches.

Authors:  M Saveria Campo; Richard B S Roden
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

10.  Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein.

Authors:  Monica E Embers; Lynn R Budgeon; Martin Pickel; Neil D Christensen
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.